Advertisement

Pharmacology of Sexual Function

  • Andreas Meissner
  • Martin C. Michel
Chapter
Part of the Springer Specialist Surgery Series book series (SPECIALIST)

Abstract

Human sexual function involves a complex interaction between the central nervous system (CNS) and peripheral organs. The CNS receives and integrates tactile, olfactory, auditory, visual, and mental stimuli to regulate various domains of sexual function. This chapter will focus on three aspects of sexual function, that is, sexual desire/arousal and, in males, erection and ejaculation. While the manipulation of desire by definition requires drug effects on central nervous function, disorders of erection and ejaculation can potentially be addressed by both centrally and peripherally acting drugs. Our emphasis will be on drug mechanisms, which already are available clinically and/or are currently in clinical development. Potential issues related to ovulation and spermatogenesis will not be discussed.

Keywords

Erectile Dysfunction Sexual Function Sexual Dysfunction Sexual Desire Sexual Arousal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Masters WH, Johnson VE. Human Sexual Response. New York: Bantam; 1981.Google Scholar
  2. 2.
    Bancroft J. Sexual arousal. In: Nadel L, ed. Encyclopedia of Cognitive Science. London: Wiley; 2002:1165-1168.Google Scholar
  3. 3.
    Meston CM, Frohlich PR. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57:1012-1030.PubMedCrossRefGoogle Scholar
  4. 4.
    Halaris A. Neurochemical aspects of the sexual response cycle. CNS Spectr. 2003;8:211-216.PubMedGoogle Scholar
  5. 5.
    Hull EM, Dominguez JM. Getting his act together: roles of glutamate, nitric oxide, and dopamine in the medial preoptic area. Brain Res. 2006;1126:66-75.PubMedCrossRefGoogle Scholar
  6. 6.
    Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: influences on male sexual behavior. Physiol Behav. 2004;83:291-307.PubMedGoogle Scholar
  7. 7.
    Hull EM, Lorrain DS, Du J, et al. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav Brain Res. 1999;105:105-116.PubMedCrossRefGoogle Scholar
  8. 8.
    Rochira V, Balestrieri A, Madeo B, et al. Congenital estrogen deficiency: in search of the estrogen role in human male reproduction. Mol Cell Endocrinol. 2001; 178:107-115.PubMedCrossRefGoogle Scholar
  9. 9.
    Motofei IG, Rowland DL. The physiological basis of human sexual arousal: neuroendocrine sexual asymmetry. Int J Androl. 2005;28:78-87.PubMedCrossRefGoogle Scholar
  10. 10.
    Behre HM, Heinemann L, Morales A, et al. Rationale, design and methods of the ESPRIT study: energy, sexual desire and body PropoRtions wIth AndroGel®, testosterone 1% gel therapy, in hypogonadal men. Aging Male. 2008;11:101-106.PubMedCrossRefGoogle Scholar
  11. 11.
    Rochira V, Balestrieri A, Madeo B, et al. Congenital estrogen deficiency in men: a new syndrome with different phenotypes; clinical and therapeutic implications in men. Mol Cell Endocrinol. 2002;193:19-28.PubMedCrossRefGoogle Scholar
  12. 12.
    Wallen K. Sex and context: hormones and primate sexual motivation. Horm Behav. 2001;40:339-357.PubMedCrossRefGoogle Scholar
  13. 13.
    Stuckey BG. Female sexual function and dysfunction in the reproductive years: the influence of endogenous and exogenous sex hormones. J Sex Med. 2008;5:2282-2290.PubMedCrossRefGoogle Scholar
  14. 14.
    Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359:2005-2017.PubMedCrossRefGoogle Scholar
  15. 15.
    Schover LR. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? Fertil Steril. 2008;90:129-140.PubMedCrossRefGoogle Scholar
  16. 16.
    Bancroft J. The endocrinology of sexual arousal. J Endocrinol. 2005;186:411-427.PubMedCrossRefGoogle Scholar
  17. 17.
    Westheide J, Cvetanovska G, Albrecht C, et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med. 2008;5:2816-2826.PubMedCrossRefGoogle Scholar
  18. 18.
    Krüger THC, Hartmann U, Schedlowski M. Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans. World J Urol. 2005;23:130-138.PubMedCrossRefGoogle Scholar
  19. 19.
    Stimmel GL, Gutierrez MA. Sexual dysfunction and psychotropic medications. CNS Spectr. 2006;11 (8 Suppl 9): 24-30.PubMedGoogle Scholar
  20. 20.
    Labbate LA. Psychotropics and sexual dysfunction: the evidence and treatments. Adv Psychosom Med. 2008;29: 107-130.PubMedCrossRefGoogle Scholar
  21. 21.
    Balon R, Segraves RT. Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther. 2008;34:353-365.PubMedCrossRefGoogle Scholar
  22. 22.
    Rosen RC, Lance RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19:67-85.PubMedCrossRefGoogle Scholar
  23. 23.
    Ferger B, Shimasaki M, Ceci A, et al. Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats. Naunyn Schmiedeberg’s Arch Pharmacol. 2010; 381:573-579.CrossRefGoogle Scholar
  24. 24.
    Mölleken D, Richter-Appelt H, Stodieck S, et al. Sexual quality of life in epilepsy: correlations with sex hormone blood levels. Epilepsy Behav. 2009;14:226-231.PubMedCrossRefGoogle Scholar
  25. 25.
    Andersson K-E. Pharmacology of penile erection. Pharmacol Rev. 2001;53:417-450.PubMedGoogle Scholar
  26. 26.
    Hatzimouratidis K, Hatzichristou D. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005; 65:1621-1650.PubMedCrossRefGoogle Scholar
  27. 27.
    Miner MM, Settel AD. Centrally acting mechanisms for the treatment of male sexual dysfunction. Urol Clin North Am. 2007;34:483-496.PubMedCrossRefGoogle Scholar
  28. 28.
    Melman A, Rojas L, Christ G. Gene transfer for erectile dysfunction: will this novel therapy be accepted by urologists? Curr Opin Urol. 2009;19:595-600.PubMedCrossRefGoogle Scholar
  29. 29.
    van Dijk MM, de la Rosette JJMCH, Michel MC. Effects of a1-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287-301.PubMedCrossRefGoogle Scholar
  30. 30.
    McCarty EJ, Dinsmore WW. Premature ejaculation: treatment update. Int J STD AIDS. 2010;21:77-81.PubMedCrossRefGoogle Scholar
  31. 31.
    Melnik T, Glina S, OMjr R. Psychological intervention for premature ejaculation. Nat Rev Urol. 2009;6:501-508.PubMedCrossRefGoogle Scholar
  32. 32.
    Patel K, Hellstrom WJ. Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation. Curr Opin Investig Drugs. 2009;10: 681-690.PubMedGoogle Scholar
  33. 33.
    Sanbe A, Tanaka Y, Fujiwara Y, et al. a1-Adrenoceptors are required for normal male sexual function. Br J Pharmacol. 2007;152:332-340.PubMedCrossRefGoogle Scholar
  34. 34.
    Michel MC. The pharmacological profile of the a1A-adrenoceptor antagonist silodosin. Eur Urol Suppl. 2010;9: 486-490.CrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Andreas Meissner
    • 1
  • Martin C. Michel
    • 2
  1. 1.Department of Urology, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  2. 2.Department of Pharmacology & Pharmacotherapy, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations